|
Rep. Lindsey LaPointe
Filed: 4/14/2026
| | 10400HB4585ham001 | | LRB104 17523 BAB 36484 a |
|
|
| 1 | | AMENDMENT TO HOUSE BILL 4585
|
| 2 | | AMENDMENT NO. ______. Amend House Bill 4585 by replacing |
| 3 | | everything after the enacting clause with the following: |
| 4 | | "Section 5. The Illinois Insurance Code is amended by |
| 5 | | changing Section 370c as follows: |
| 6 | | (215 ILCS 5/370c) (from Ch. 73, par. 982c) |
| 7 | | Sec. 370c. Mental and emotional disorders. |
| 8 | | (a)(1) On and after January 1, 2022 (the effective date of |
| 9 | | Public Act 102-579), every insurer that amends, delivers, |
| 10 | | issues, or renews group accident and health policies providing |
| 11 | | coverage for hospital or medical treatment or services for |
| 12 | | illness shall provide coverage for the medically necessary |
| 13 | | treatment of mental, emotional, nervous, or substance use |
| 14 | | disorders or conditions consistent with the parity |
| 15 | | requirements of Section 370c.1 of this Code. |
| 16 | | (2) Each insured that is covered for mental, emotional, |
|
| | 10400HB4585ham001 | - 2 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | nervous, or substance use disorders or conditions shall be |
| 2 | | free to select the physician licensed to practice medicine in |
| 3 | | all its branches, licensed clinical psychologist, licensed |
| 4 | | clinical social worker, licensed clinical professional |
| 5 | | counselor, licensed marriage and family therapist, licensed |
| 6 | | speech-language pathologist, or other licensed or certified |
| 7 | | professional at a program licensed pursuant to the Substance |
| 8 | | Use Disorder Act of his or her choice to treat such disorders, |
| 9 | | and the insurer shall pay the covered charges of such |
| 10 | | physician licensed to practice medicine in all its branches, |
| 11 | | licensed clinical psychologist, licensed clinical social |
| 12 | | worker, licensed clinical professional counselor, licensed |
| 13 | | marriage and family therapist, licensed speech-language |
| 14 | | pathologist, or other licensed or certified professional at a |
| 15 | | program licensed pursuant to the Substance Use Disorder Act up |
| 16 | | to the limits of coverage, provided (i) the disorder or |
| 17 | | condition treated is covered by the policy, and (ii) the |
| 18 | | physician, licensed psychologist, licensed clinical social |
| 19 | | worker, licensed clinical professional counselor, licensed |
| 20 | | marriage and family therapist, licensed speech-language |
| 21 | | pathologist, or other licensed or certified professional at a |
| 22 | | program licensed pursuant to the Substance Use Disorder Act is |
| 23 | | authorized to provide said services under the statutes of this |
| 24 | | State and in accordance with accepted principles of his or her |
| 25 | | profession. |
| 26 | | (3) Insofar as this Section applies solely to licensed |
|
| | 10400HB4585ham001 | - 3 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | clinical social workers, licensed clinical professional |
| 2 | | counselors, licensed marriage and family therapists, licensed |
| 3 | | speech-language pathologists, and other licensed or certified |
| 4 | | professionals at programs licensed pursuant to the Substance |
| 5 | | Use Disorder Act, those persons who may provide services to |
| 6 | | individuals shall do so after the licensed clinical social |
| 7 | | worker, licensed clinical professional counselor, licensed |
| 8 | | marriage and family therapist, licensed speech-language |
| 9 | | pathologist, or other licensed or certified professional at a |
| 10 | | program licensed pursuant to the Substance Use Disorder Act |
| 11 | | has informed the patient of the desirability of the patient |
| 12 | | conferring with the patient's primary care physician. |
| 13 | | (4) "Mental, emotional, nervous, or substance use disorder |
| 14 | | or condition" means a condition or disorder that involves a |
| 15 | | mental health condition or substance use disorder that falls |
| 16 | | under any of the diagnostic categories listed in the mental |
| 17 | | and behavioral disorders chapter of the current edition of the |
| 18 | | World Health Organization's International Classification of |
| 19 | | Disease or that is listed in the most recent version of the |
| 20 | | American Psychiatric Association's Diagnostic and Statistical |
| 21 | | Manual of Mental Disorders. "Mental, emotional, nervous, or |
| 22 | | substance use disorder or condition" includes any mental |
| 23 | | health condition that occurs during pregnancy or during the |
| 24 | | postpartum period and includes, but is not limited to, |
| 25 | | postpartum depression. |
| 26 | | (5) Medically necessary treatment and medical necessity |
|
| | 10400HB4585ham001 | - 4 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | determinations shall be interpreted and made in a manner that |
| 2 | | is consistent with and pursuant to subsections (h) through |
| 3 | | (y). |
| 4 | | (b)(1) (Blank). |
| 5 | | (2) (Blank). |
| 6 | | (2.5) (Blank). |
| 7 | | (3) Unless otherwise prohibited by federal law and |
| 8 | | consistent with the parity requirements of Section 370c.1 of |
| 9 | | this Code, the insurer that amends, delivers, issues, or |
| 10 | | renews a group or individual policy of accident and health |
| 11 | | insurance, a qualified health plan offered through the health |
| 12 | | insurance marketplace, or a provider of treatment of mental, |
| 13 | | emotional, nervous, or substance use disorders or conditions |
| 14 | | shall furnish medical records or other necessary data that |
| 15 | | substantiate that initial or continued treatment is at all |
| 16 | | times medically necessary. Nothing in this paragraph (3) |
| 17 | | supersedes the prohibition on prior authorization requirements |
| 18 | | to the extent provided under subsections (g) and (w) and |
| 19 | | subparagraph (A) of paragraph (6.5) of this subsection. |
| 20 | | Nothing prevents the insured from agreeing in writing to |
| 21 | | continue treatment at his or her expense. When making a |
| 22 | | determination of the medical necessity for a treatment |
| 23 | | modality for mental, emotional, nervous, or substance use |
| 24 | | disorders or conditions, an insurer must make the |
| 25 | | determination in a manner that is consistent with the manner |
| 26 | | used to make that determination with respect to other diseases |
|
| | 10400HB4585ham001 | - 5 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | or illnesses covered under the policy, including an appeals |
| 2 | | process. Medical necessity determinations for substance use |
| 3 | | disorders shall be made in accordance with appropriate patient |
| 4 | | placement criteria established by the American Society of |
| 5 | | Addiction Medicine. No additional criteria may be used to make |
| 6 | | medical necessity determinations for substance use disorders. |
| 7 | | (4) A group health benefit plan amended, delivered, |
| 8 | | issued, or renewed on or after January 1, 2019 (the effective |
| 9 | | date of Public Act 100-1024) or an individual policy of |
| 10 | | accident and health insurance or a qualified health plan |
| 11 | | offered through the health insurance marketplace amended, |
| 12 | | delivered, issued, or renewed on or after January 1, 2019 (the |
| 13 | | effective date of Public Act 100-1024): |
| 14 | | (A) shall provide coverage based upon medical |
| 15 | | necessity for the treatment of a mental, emotional, |
| 16 | | nervous, or substance use disorder or condition consistent |
| 17 | | with the parity requirements of Section 370c.1 of this |
| 18 | | Code; provided, however, that in each calendar year |
| 19 | | coverage shall not be less than the following: |
| 20 | | (i) 45 days of inpatient treatment; and |
| 21 | | (ii) beginning on June 26, 2006 (the effective |
| 22 | | date of Public Act 94-921), 60 visits for outpatient |
| 23 | | treatment including group and individual outpatient |
| 24 | | treatment; and |
| 25 | | (iii) for plans or policies delivered, issued for |
| 26 | | delivery, renewed, or modified after January 1, 2007 |
|
| | 10400HB4585ham001 | - 6 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | (the effective date of Public Act 94-906), 20 |
| 2 | | additional outpatient visits for speech therapy for |
| 3 | | treatment of pervasive developmental disorders that |
| 4 | | will be in addition to speech therapy provided |
| 5 | | pursuant to item (ii) of this subparagraph (A); and |
| 6 | | (B) may not include a lifetime limit on the number of |
| 7 | | days of inpatient treatment or the number of outpatient |
| 8 | | visits covered under the plan. |
| 9 | | (C) (Blank). |
| 10 | | (5) An issuer of a group health benefit plan or an |
| 11 | | individual policy of accident and health insurance or a |
| 12 | | qualified health plan offered through the health insurance |
| 13 | | marketplace may not count toward the number of outpatient |
| 14 | | visits required to be covered under this Section an outpatient |
| 15 | | visit for the purpose of medication management and shall cover |
| 16 | | the outpatient visits under the same terms and conditions as |
| 17 | | it covers outpatient visits for the treatment of physical |
| 18 | | illness. |
| 19 | | (5.5) An individual or group health benefit plan amended, |
| 20 | | delivered, issued, or renewed on or after September 9, 2015 |
| 21 | | (the effective date of Public Act 99-480) shall offer coverage |
| 22 | | for medically necessary acute treatment services and medically |
| 23 | | necessary clinical stabilization services. The treating |
| 24 | | provider shall base all treatment recommendations and the |
| 25 | | health benefit plan shall base all medical necessity |
| 26 | | determinations for substance use disorders in accordance with |
|
| | 10400HB4585ham001 | - 7 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | the most current edition of the Treatment Criteria for |
| 2 | | Addictive, Substance-Related, and Co-Occurring Conditions |
| 3 | | established by the American Society of Addiction Medicine. The |
| 4 | | treating provider shall base all treatment recommendations and |
| 5 | | the health benefit plan shall base all medical necessity |
| 6 | | determinations for medication-assisted treatment in accordance |
| 7 | | with the most current Treatment Criteria for Addictive, |
| 8 | | Substance-Related, and Co-Occurring Conditions established by |
| 9 | | the American Society of Addiction Medicine. |
| 10 | | As used in this subsection: |
| 11 | | "Acute treatment services" means 24-hour medically |
| 12 | | supervised addiction treatment that provides evaluation and |
| 13 | | withdrawal management and may include biopsychosocial |
| 14 | | assessment, individual and group counseling, psychoeducational |
| 15 | | groups, and discharge planning. |
| 16 | | "Clinical stabilization services" means 24-hour treatment, |
| 17 | | usually following acute treatment services for substance |
| 18 | | abuse, which may include intensive education and counseling |
| 19 | | regarding the nature of addiction and its consequences, |
| 20 | | relapse prevention, outreach to families and significant |
| 21 | | others, and aftercare planning for individuals beginning to |
| 22 | | engage in recovery from addiction. |
| 23 | | "Prior authorization" has the meaning given to that term |
| 24 | | in Section 15 of the Prior Authorization Reform Act. |
| 25 | | (6) An issuer of a group health benefit plan may provide or |
| 26 | | offer coverage required under this Section through a managed |
|
| | 10400HB4585ham001 | - 8 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | care plan. |
| 2 | | (6.5) An individual or group health benefit plan amended, |
| 3 | | delivered, issued, or renewed on or after January 1, 2019 (the |
| 4 | | effective date of Public Act 100-1024): |
| 5 | | (A) shall not impose prior authorization requirements, |
| 6 | | including limitations on dosage, other than those |
| 7 | | established under the Treatment Criteria for Addictive, |
| 8 | | Substance-Related, and Co-Occurring Conditions |
| 9 | | established by the American Society of Addiction Medicine, |
| 10 | | on a prescription medication approved by the United States |
| 11 | | Food and Drug Administration that is prescribed or |
| 12 | | administered for the treatment of substance use disorders; |
| 13 | | (B) shall not impose any step therapy requirements; |
| 14 | | (C) shall place all prescription medications approved |
| 15 | | by the United States Food and Drug Administration |
| 16 | | prescribed or administered for the treatment of substance |
| 17 | | use disorders on, for brand medications, the lowest tier |
| 18 | | of the drug formulary developed and maintained by the |
| 19 | | individual or group health benefit plan that covers brand |
| 20 | | medications and, for generic medications, the lowest tier |
| 21 | | of the drug formulary developed and maintained by the |
| 22 | | individual or group health benefit plan that covers |
| 23 | | generic medications; and |
| 24 | | (D) shall not exclude coverage for a prescription |
| 25 | | medication approved by the United States Food and Drug |
| 26 | | Administration for the treatment of substance use |
|
| | 10400HB4585ham001 | - 9 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | disorders and any associated counseling or wraparound |
| 2 | | services on the grounds that such medications and services |
| 3 | | were court ordered. |
| 4 | | (7) (Blank). |
| 5 | | (8) (Blank). |
| 6 | | (9) With respect to all mental, emotional, nervous, or |
| 7 | | substance use disorders or conditions, coverage for inpatient |
| 8 | | treatment shall include coverage for treatment in a |
| 9 | | residential treatment center certified or licensed by the |
| 10 | | Department of Public Health or the Department of Human |
| 11 | | Services. |
| 12 | | (A) Coverage for treatment in a residential treatment |
| 13 | | center shall include residential coverage for the |
| 14 | | diagnosis and treatment of substance use disorders, |
| 15 | | including at American Society of Addiction Medicine levels |
| 16 | | of treatment 3.5 (Clinically Managed High-Intensity |
| 17 | | Residential) and 3.7 (Medically Managed Residential). This |
| 18 | | coverage shall include medically necessary treatment for |
| 19 | | substance use disorder treatment services provided in |
| 20 | | residential settings. This coverage shall not apply |
| 21 | | financial requirements or treatment limitations, including |
| 22 | | concurrent or utilization review requirements, to |
| 23 | | residential substance use disorder benefits that are more |
| 24 | | restrictive than the predominant financial requirements |
| 25 | | and treatment limitations applied to other medical and |
| 26 | | surgical benefits covered by the policy. |
|
| | 10400HB4585ham001 | - 10 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | (B) Coverage for treatment in a residential treatment |
| 2 | | center may be subject to annual deductibles, coinsurance, |
| 3 | | or other cost sharing that is consistent with those |
| 4 | | imposed on other benefits covered by the policy. |
| 5 | | (C) This paragraph (9) shall apply to facilities in |
| 6 | | this State that are licensed, certified, or otherwise |
| 7 | | authorized and participating in a provider network. |
| 8 | | Coverage for treatment in a residential treatment center |
| 9 | | shall not be subject to prior authorization and shall not |
| 10 | | be subject to concurrent utilization review during the |
| 11 | | first 3 days of American Society of Addiction Medicine |
| 12 | | Level 3.7 and the first 28 days of American Society of |
| 13 | | Addiction Medicine Level 3.5 residential admission, so |
| 14 | | long as the facility notifies the insurer of both the |
| 15 | | admission and the initial treatment plan within the |
| 16 | | notification periods set forth in subsection (g). The |
| 17 | | facility shall perform clinical review of the patient, |
| 18 | | including consultation with the insurer at or just prior |
| 19 | | to the 14th day of treatment to ensure that the facility is |
| 20 | | using the American Society of Addiction Medicine patient |
| 21 | | placement criteria to ensure that the residential |
| 22 | | treatment is medically necessary for the patient. |
| 23 | | (D) Prior to discharge, in addition to the notice |
| 24 | | required under subsection (g), the facility shall provide |
| 25 | | the patient and the insurer with a written discharge plan, |
| 26 | | which shall describe arrangements for additional services |
|
| | 10400HB4585ham001 | - 11 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | needed following discharge from the residential facility, |
| 2 | | as determined using the American Society of Addiction |
| 3 | | Medicine patient placement criteria used by the insurer |
| 4 | | and designated by the relevant Illinois State agencies. |
| 5 | | Prior to discharge, the facility shall indicate to the |
| 6 | | insurer whether services included in the discharge plan |
| 7 | | are secured or determined to be reasonably available. |
| 8 | | (E) An insured shall not have any financial obligation |
| 9 | | to the facility for any services provided during |
| 10 | | residential treatment, including all services provided |
| 11 | | during the first 35 days of residential treatment, other |
| 12 | | than any copayment, coinsurance, or deductible otherwise |
| 13 | | required under the policy. The American Society of |
| 14 | | Addiction Medicine patient placement criteria for medical |
| 15 | | necessity determinations under the policy with respect to |
| 16 | | residential substance use disorder benefits shall be made |
| 17 | | available by the insurer to any insured, prospective |
| 18 | | insured, or in-network provider upon request. |
| 19 | | (c) This Section shall not be interpreted to require |
| 20 | | coverage for speech therapy or other habilitative services for |
| 21 | | those individuals covered under Section 356z.15 of this Code. |
| 22 | | (d) With respect to a group or individual policy of |
| 23 | | accident and health insurance or a qualified health plan |
| 24 | | offered through the health insurance marketplace, the |
| 25 | | Department and, with respect to medical assistance, the |
| 26 | | Department of Healthcare and Family Services shall each |
|
| | 10400HB4585ham001 | - 12 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | enforce the requirements of this Section and Sections 356z.23 |
| 2 | | and 370c.1 of this Code, the Paul Wellstone and Pete Domenici |
| 3 | | Mental Health Parity and Addiction Equity Act of 2008, 42 |
| 4 | | U.S.C. 18031(j), and any amendments to, and federal guidance |
| 5 | | or regulations issued under, those Acts, including, but not |
| 6 | | limited to, final regulations issued under the Paul Wellstone |
| 7 | | and Pete Domenici Mental Health Parity and Addiction Equity |
| 8 | | Act of 2008 and final regulations applying the Paul Wellstone |
| 9 | | and Pete Domenici Mental Health Parity and Addiction Equity |
| 10 | | Act of 2008 to Medicaid managed care organizations, the |
| 11 | | Children's Health Insurance Program, and alternative benefit |
| 12 | | plans. Specifically, the Department and the Department of |
| 13 | | Healthcare and Family Services shall take action: |
| 14 | | (1) proactively ensuring compliance by individual and |
| 15 | | group policies, including by requiring that insurers |
| 16 | | submit comparative analyses, as set forth in paragraph (6) |
| 17 | | of subsection (k) of Section 370c.1, demonstrating how |
| 18 | | they design and apply nonquantitative treatment |
| 19 | | limitations, both as written and in operation, for mental, |
| 20 | | emotional, nervous, or substance use disorder or condition |
| 21 | | benefits as compared to how they design and apply |
| 22 | | nonquantitative treatment limitations, as written and in |
| 23 | | operation, for medical and surgical benefits; |
| 24 | | (2) evaluating all consumer or provider complaints |
| 25 | | regarding mental, emotional, nervous, or substance use |
| 26 | | disorder or condition coverage for possible parity |
|
| | 10400HB4585ham001 | - 13 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | violations; |
| 2 | | (3) performing parity compliance market conduct |
| 3 | | examinations or, in the case of the Department of |
| 4 | | Healthcare and Family Services, parity compliance audits |
| 5 | | of individual and group plans and policies, including, but |
| 6 | | not limited to, reviews of: |
| 7 | | (A) nonquantitative treatment limitations, |
| 8 | | including, but not limited to, prior authorization |
| 9 | | requirements, concurrent review, retrospective review, |
| 10 | | step therapy, network admission standards, |
| 11 | | reimbursement rates, and geographic restrictions; |
| 12 | | (B) denials of authorization, payment, and |
| 13 | | coverage; and |
| 14 | | (C) other specific criteria as may be determined |
| 15 | | by the Department. |
| 16 | | The findings and the conclusions of the parity compliance |
| 17 | | market conduct examinations and audits shall be made public. |
| 18 | | The Director may adopt rules to effectuate any provisions |
| 19 | | of the Paul Wellstone and Pete Domenici Mental Health Parity |
| 20 | | and Addiction Equity Act of 2008 that relate to the business of |
| 21 | | insurance. |
| 22 | | (e) Availability of plan information. |
| 23 | | (1) The criteria for medical necessity determinations |
| 24 | | made under a group health plan, an individual policy of |
| 25 | | accident and health insurance, or a qualified health plan |
| 26 | | offered through the health insurance marketplace with |
|
| | 10400HB4585ham001 | - 14 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | respect to mental health or substance use disorder |
| 2 | | benefits (or health insurance coverage offered in |
| 3 | | connection with the plan with respect to such benefits) |
| 4 | | must be made available by the plan administrator (or the |
| 5 | | health insurance issuer offering such coverage) to any |
| 6 | | current or potential participant, beneficiary, or |
| 7 | | contracting provider upon request. |
| 8 | | (2) The reason for any denial under a group health |
| 9 | | benefit plan, an individual policy of accident and health |
| 10 | | insurance, or a qualified health plan offered through the |
| 11 | | health insurance marketplace (or health insurance coverage |
| 12 | | offered in connection with such plan or policy) of |
| 13 | | reimbursement or payment for services with respect to |
| 14 | | mental, emotional, nervous, or substance use disorders or |
| 15 | | conditions benefits in the case of any participant or |
| 16 | | beneficiary must be made available within a reasonable |
| 17 | | time and in a reasonable manner and in readily |
| 18 | | understandable language by the plan administrator (or the |
| 19 | | health insurance issuer offering such coverage) to the |
| 20 | | participant or beneficiary upon request. |
| 21 | | (f) As used in this Section, "group policy of accident and |
| 22 | | health insurance" and "group health benefit plan" includes (1) |
| 23 | | State-regulated employer-sponsored group health insurance |
| 24 | | plans written in Illinois or which purport to provide coverage |
| 25 | | for a resident of this State; and (2) State, county, |
| 26 | | municipal, or school district employee health plans. |
|
| | 10400HB4585ham001 | - 15 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | References to an insurer include all plans described in this |
| 2 | | subsection. |
| 3 | | (g) (1) As used in this subsection: |
| 4 | | "Benefits", with respect to insurers that are not Medicaid |
| 5 | | managed care organizations, means the benefits provided for |
| 6 | | treatment services for inpatient and outpatient treatment of |
| 7 | | substance use disorders or conditions at American Society of |
| 8 | | Addiction Medicine levels of treatment 2.1 (Intensive |
| 9 | | Outpatient), 2.5 (High-Intensity Outpatient), 3.1 (Clinically |
| 10 | | Managed Low-Intensity Residential), 3.5 (Clinically Managed |
| 11 | | High-Intensity Residential), and 3.7 (Medically Managed |
| 12 | | Residential) and OMT (Opioid Maintenance Therapy) services. |
| 13 | | "Benefits", with respect to Medicaid managed care |
| 14 | | organizations, means the benefits provided for treatment |
| 15 | | services for inpatient and outpatient treatment of substance |
| 16 | | use disorders or conditions at American Society of Addiction |
| 17 | | Medicine levels of treatment 2.1 (Intensive Outpatient), 2.5 |
| 18 | | (High-Intensity Outpatient), 3.5 (Clinically Managed |
| 19 | | High-Intensity Residential), and 3.7 (Medically Managed |
| 20 | | Residential) and OMT (Opioid Maintenance Therapy) services. |
| 21 | | "Substance use disorder treatment provider or facility" |
| 22 | | means a licensed physician, licensed psychologist, licensed |
| 23 | | psychiatrist, licensed advanced practice registered nurse, or |
| 24 | | licensed, certified, or otherwise State-approved facility or |
| 25 | | provider of substance use disorder treatment. |
| 26 | | (2) A group health insurance policy, an individual health |
|
| | 10400HB4585ham001 | - 16 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | benefit plan, or qualified health plan that is offered through |
| 2 | | the health insurance marketplace, small employer group health |
| 3 | | plan, and large employer group health plan that is amended, |
| 4 | | delivered, issued, executed, or renewed in this State, or |
| 5 | | approved for issuance or renewal in this State, on or after |
| 6 | | January 1, 2019 (the effective date of Public Act 100-1023) |
| 7 | | shall comply with the requirements of this Section and Section |
| 8 | | 370c.1. The services for the treatment and the ongoing |
| 9 | | assessment of the patient's progress in treatment shall follow |
| 10 | | the requirements of 77 Ill. Adm. Code 2060. |
| 11 | | (3) Prior authorization shall not be utilized for the |
| 12 | | benefits under this subsection. Except to the extent |
| 13 | | prohibited by Section 370c.1 with respect to treatment |
| 14 | | limitations in a benefit classification or subclassification, |
| 15 | | the insurer may require the substance use disorder treatment |
| 16 | | provider or facility to notify the insurer of the initiation |
| 17 | | of treatment. For an insurer that is not a Medicaid managed |
| 18 | | care organization, the substance use disorder treatment |
| 19 | | provider or facility may be required to give notification for |
| 20 | | the initiation of treatment of the covered person within 2 |
| 21 | | business days. For Medicaid managed care organizations, the |
| 22 | | substance use disorder treatment provider or facility may be |
| 23 | | required to give notification in accordance with the protocol |
| 24 | | set forth in the provider agreement for initiation of |
| 25 | | treatment within 24 hours. If the Medicaid managed care |
| 26 | | organization is not capable of accepting the notification in |
|
| | 10400HB4585ham001 | - 17 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | accordance with the contractual protocol during the 24-hour |
| 2 | | period following admission, the substance use disorder |
| 3 | | treatment provider or facility shall have one additional |
| 4 | | business day to provide the notification to the appropriate |
| 5 | | managed care organization. Treatment plans shall be developed |
| 6 | | in accordance with the requirements and timeframes established |
| 7 | | in 77 Ill. Adm. Code 2060. No such coverage shall be subject to |
| 8 | | concurrent review prior to the applicable notification |
| 9 | | deadline. If coverage is denied retrospectively, neither the |
| 10 | | provider or facility nor the insurer shall bill, and the |
| 11 | | covered individual shall not be liable, for any treatment |
| 12 | | under this subsection through the date the adverse |
| 13 | | determination is issued, other than any copayment, |
| 14 | | coinsurance, or deductible for the treatment or stay through |
| 15 | | that date as applicable under the policy. Coverage shall not |
| 16 | | be retrospectively denied for benefits that were furnished at |
| 17 | | a participating substance use disorder facility prior to the |
| 18 | | applicable notification deadline except for the following: |
| 19 | | (A) upon reasonable determination that the benefits |
| 20 | | were not provided; |
| 21 | | (B) upon determination that the patient receiving the |
| 22 | | treatment was not an insured, enrollee, or beneficiary |
| 23 | | under the policy; |
| 24 | | (C) upon material misrepresentation by the patient or |
| 25 | | provider. As used in this subparagraph (C), "material" |
| 26 | | means a fact or situation that is not merely technical in |
|
| | 10400HB4585ham001 | - 18 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | nature and results or could result in a substantial change |
| 2 | | in the situation; |
| 3 | | (D) upon determination that a service was excluded |
| 4 | | under the terms of coverage. For situations that qualify |
| 5 | | under this subparagraph (D), the limitation to billing for |
| 6 | | a copayment, coinsurance, or deductible shall not apply; |
| 7 | | (E) upon determination that a service was not |
| 8 | | medically necessary consistent with subsections (h) |
| 9 | | through (n); or |
| 10 | | (F) upon determination that the patient did not |
| 11 | | consent to the treatment and that there was no court order |
| 12 | | mandating the treatment. |
| 13 | | (4) For an insurer that is not a Medicaid managed care |
| 14 | | organization, if an insurer determines that benefits are no |
| 15 | | longer medically necessary, the insurer shall notify the |
| 16 | | covered person, the covered person's authorized |
| 17 | | representative, if any, and the covered person's health care |
| 18 | | provider in writing of the covered person's right to request |
| 19 | | an external review pursuant to the Health Carrier External |
| 20 | | Review Act. The notification shall occur within 24 hours |
| 21 | | following the adverse determination. |
| 22 | | Pursuant to the requirements of the Health Carrier |
| 23 | | External Review Act, the covered person or the covered |
| 24 | | person's authorized representative may request an expedited |
| 25 | | external review. An expedited external review may not occur if |
| 26 | | the substance use disorder treatment provider or facility |
|
| | 10400HB4585ham001 | - 19 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | determines that continued treatment is no longer medically |
| 2 | | necessary. |
| 3 | | If an expedited external review request meets the criteria |
| 4 | | of the Health Carrier External Review Act, an independent |
| 5 | | review organization shall make a final determination of |
| 6 | | medical necessity within 72 hours. If an independent review |
| 7 | | organization upholds an adverse determination, an insurer |
| 8 | | shall remain responsible to provide coverage of benefits |
| 9 | | through the day following the determination of the independent |
| 10 | | review organization. A decision to reverse an adverse |
| 11 | | determination shall comply with the Health Carrier External |
| 12 | | Review Act. |
| 13 | | (5) The substance use disorder treatment provider or |
| 14 | | facility shall provide the insurer with 7 business days' |
| 15 | | advance notice of the planned discharge of the patient from |
| 16 | | the substance use disorder treatment provider or facility and |
| 17 | | notice on the day that the patient is discharged from the |
| 18 | | substance use disorder treatment provider or facility. |
| 19 | | (6) The benefits required by this subsection shall be |
| 20 | | provided to all covered persons with a diagnosis of substance |
| 21 | | use disorder or conditions. The presence of additional related |
| 22 | | or unrelated diagnoses shall not be a basis to reduce or deny |
| 23 | | the benefits required by this subsection. |
| 24 | | (7) Nothing in this subsection shall be construed to |
| 25 | | require an insurer to provide coverage for any of the benefits |
| 26 | | in this subsection. |
|
| | 10400HB4585ham001 | - 20 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | (8) Any concurrent or retrospective review permitted by |
| 2 | | this subsection must be consistent with the utilization review |
| 3 | | provisions in subsections (h) through (n). |
| 4 | | (h) As used in this Section: |
| 5 | | "Generally accepted standards of mental, emotional, |
| 6 | | nervous, or substance use disorder or condition care" means |
| 7 | | standards of care and clinical practice that are generally |
| 8 | | recognized by health care providers practicing in relevant |
| 9 | | clinical specialties such as psychiatry, psychology, clinical |
| 10 | | sociology, social work, addiction medicine and counseling, and |
| 11 | | behavioral health treatment. Valid, evidence-based sources |
| 12 | | reflecting generally accepted standards of mental, emotional, |
| 13 | | nervous, or substance use disorder or condition care include |
| 14 | | peer-reviewed scientific studies and medical literature, |
| 15 | | recommendations of nonprofit health care provider professional |
| 16 | | associations and specialty societies, including, but not |
| 17 | | limited to, patient placement criteria and clinical practice |
| 18 | | guidelines, recommendations of federal government agencies, |
| 19 | | and drug labeling approved by the United States Food and Drug |
| 20 | | Administration. |
| 21 | | "Medically necessary treatment of mental, emotional, |
| 22 | | nervous, or substance use disorders or conditions" means a |
| 23 | | service or product addressing the specific needs of that |
| 24 | | patient, for the purpose of screening, preventing, diagnosing, |
| 25 | | managing, or treating an illness, injury, or condition or its |
| 26 | | symptoms and comorbidities, including minimizing the |
|
| | 10400HB4585ham001 | - 21 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | progression of an illness, injury, or condition or its |
| 2 | | symptoms and comorbidities in a manner that is all of the |
| 3 | | following: |
| 4 | | (1) in accordance with the generally accepted |
| 5 | | standards of mental, emotional, nervous, or substance use |
| 6 | | disorder or condition care; |
| 7 | | (2) clinically appropriate in terms of type, |
| 8 | | frequency, extent, site, and duration; and |
| 9 | | (3) not primarily for the economic benefit of the |
| 10 | | insurer, purchaser, or for the convenience of the patient, |
| 11 | | treating physician, or other health care provider. |
| 12 | | "Utilization review" means either of the following: |
| 13 | | (1) prospectively, retrospectively, or concurrently |
| 14 | | reviewing and approving, modifying, delaying, or denying, |
| 15 | | based in whole or in part on medical necessity, requests |
| 16 | | by health care providers, insureds, or their authorized |
| 17 | | representatives for coverage of health care services |
| 18 | | before, retrospectively, or concurrently with the |
| 19 | | provision of health care services to insureds. |
| 20 | | (2) evaluating the medical necessity, appropriateness, |
| 21 | | level of care, service intensity, efficacy, or efficiency |
| 22 | | of health care services, benefits, procedures, or |
| 23 | | settings, under any circumstances, to determine whether a |
| 24 | | health care service or benefit subject to a medical |
| 25 | | necessity coverage requirement in an insurance policy is |
| 26 | | covered as medically necessary for an insured. |
|
| | 10400HB4585ham001 | - 22 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | "Utilization review criteria" means patient placement |
| 2 | | criteria or any criteria, standards, protocols, or guidelines |
| 3 | | used by an insurer to conduct utilization review. |
| 4 | | (i)(1) Every insurer that amends, delivers, issues, or |
| 5 | | renews a group or individual policy of accident and health |
| 6 | | insurance or a qualified health plan offered through the |
| 7 | | health insurance marketplace in this State and Medicaid |
| 8 | | managed care organizations providing coverage for hospital or |
| 9 | | medical treatment on or after January 1, 2023 shall, pursuant |
| 10 | | to subsections (h) through (s), provide coverage for medically |
| 11 | | necessary treatment of mental, emotional, nervous, or |
| 12 | | substance use disorders or conditions. |
| 13 | | (2) An insurer shall not set a specific limit on the |
| 14 | | duration of benefits or coverage of medically necessary |
| 15 | | treatment of mental, emotional, nervous, or substance use |
| 16 | | disorders or conditions or limit coverage only to alleviation |
| 17 | | of the insured's current symptoms. |
| 18 | | (3) All utilization review conducted by the insurer |
| 19 | | concerning diagnosis, prevention, and treatment of insureds |
| 20 | | diagnosed with mental, emotional, nervous, or substance use |
| 21 | | disorders or conditions shall be conducted in accordance with |
| 22 | | the requirements of subsections (k) through (w). |
| 23 | | (4) An insurer that authorizes a specific type of |
| 24 | | treatment by a provider pursuant to this Section shall not |
| 25 | | rescind or modify the authorization after that provider |
| 26 | | renders the health care service in good faith and pursuant to |
|
| | 10400HB4585ham001 | - 23 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | this authorization for any reason, including, but not limited |
| 2 | | to, the insurer's subsequent cancellation or modification of |
| 3 | | the insured's or policyholder's contract, or the insured's or |
| 4 | | policyholder's eligibility. Nothing in this Section shall |
| 5 | | require the insurer to cover a treatment when the |
| 6 | | authorization was granted based on a material |
| 7 | | misrepresentation by the insured, the policyholder, or the |
| 8 | | provider. Nothing in this Section shall require Medicaid |
| 9 | | managed care organizations to pay for services if the |
| 10 | | individual was not eligible for Medicaid at the time the |
| 11 | | service was rendered. Nothing in this Section shall require an |
| 12 | | insurer to pay for services if the individual was not the |
| 13 | | insurer's enrollee at the time services were rendered. As used |
| 14 | | in this paragraph, "material" means a fact or situation that |
| 15 | | is not merely technical in nature and results in or could |
| 16 | | result in a substantial change in the situation. |
| 17 | | (j) An insurer shall not limit benefits or coverage for |
| 18 | | medically necessary services on the basis that those services |
| 19 | | should be or could be covered by a public entitlement program, |
| 20 | | including, but not limited to, special education or an |
| 21 | | individualized education program, Medicaid, Medicare, |
| 22 | | Supplemental Security Income, or Social Security Disability |
| 23 | | Insurance, and shall not include or enforce a contract term |
| 24 | | that excludes otherwise covered benefits on the basis that |
| 25 | | those services should be or could be covered by a public |
| 26 | | entitlement program. Nothing in this subsection shall be |
|
| | 10400HB4585ham001 | - 24 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | construed to require an insurer to cover benefits that have |
| 2 | | been authorized and provided for a covered person by a public |
| 3 | | entitlement program. Medicaid managed care organizations are |
| 4 | | not subject to this subsection. |
| 5 | | (k) An insurer shall base any medical necessity |
| 6 | | determination or the utilization review criteria that the |
| 7 | | insurer, and any entity acting on the insurer's behalf, |
| 8 | | applies to determine the medical necessity of health care |
| 9 | | services and benefits for the diagnosis, prevention, and |
| 10 | | treatment of mental, emotional, nervous, or substance use |
| 11 | | disorders or conditions on current generally accepted |
| 12 | | standards of mental, emotional, nervous, or substance use |
| 13 | | disorder or condition care. All denials and appeals shall be |
| 14 | | reviewed by a professional with experience or expertise |
| 15 | | comparable to the provider requesting the authorization. |
| 16 | | (l) In conducting utilization review of all covered health |
| 17 | | care services for the diagnosis, prevention, and treatment of |
| 18 | | mental, emotional, and nervous disorders or conditions, an |
| 19 | | insurer shall apply the criteria and guidelines set forth in |
| 20 | | the most recent version of the treatment criteria developed by |
| 21 | | an unaffiliated nonprofit professional association for the |
| 22 | | relevant clinical specialty or, for Medicaid managed care |
| 23 | | organizations, criteria and guidelines determined by the |
| 24 | | Department of Healthcare and Family Services that are |
| 25 | | consistent with generally accepted standards of mental, |
| 26 | | emotional, nervous or substance use disorder or condition |
|
| | 10400HB4585ham001 | - 25 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | care. Pursuant to subsection (b), in conducting utilization |
| 2 | | review of all covered services and benefits for the diagnosis, |
| 3 | | prevention, and treatment of substance use disorders an |
| 4 | | insurer shall use the most recent edition of the patient |
| 5 | | placement criteria established by the American Society of |
| 6 | | Addiction Medicine. |
| 7 | | (m) In conducting utilization review relating to level of |
| 8 | | care placement, continued stay, transfer, discharge, or any |
| 9 | | other patient care decisions that are within the scope of the |
| 10 | | sources specified in subsection (l), an insurer shall not |
| 11 | | apply different, additional, conflicting, or more restrictive |
| 12 | | utilization review criteria than the criteria set forth in |
| 13 | | those sources. For all level of care placement decisions, the |
| 14 | | insurer shall authorize placement at the level of care |
| 15 | | consistent with the assessment of the insured using the |
| 16 | | relevant patient placement criteria as specified in subsection |
| 17 | | (l). If that level of placement is not available, the insurer |
| 18 | | shall authorize the next higher level of care. In the event of |
| 19 | | disagreement, the insurer shall provide full detail of its |
| 20 | | assessment using the relevant criteria as specified in |
| 21 | | subsection (l) to the provider of the service and the patient. |
| 22 | | If an insurer purchases or licenses utilization review |
| 23 | | criteria pursuant to this subsection, the insurer shall verify |
| 24 | | and document before use that the criteria were developed in |
| 25 | | accordance with subsection (k). |
| 26 | | (n) In conducting utilization review that is outside the |
|
| | 10400HB4585ham001 | - 26 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | scope of the criteria as specified in subsection (l) or |
| 2 | | relates to the advancements in technology or in the types or |
| 3 | | levels of care that are not addressed in the most recent |
| 4 | | versions of the sources specified in subsection (l), an |
| 5 | | insurer shall conduct utilization review in accordance with |
| 6 | | subsection (k). |
| 7 | | (o) This Section does not in any way limit the rights of a |
| 8 | | patient under the Medical Patient Rights Act. |
| 9 | | (p) This Section does not in any way limit early and |
| 10 | | periodic screening, diagnostic, and treatment benefits as |
| 11 | | defined under 42 U.S.C. 1396d(r). |
| 12 | | (q) To ensure the proper use of the criteria described in |
| 13 | | subsection (l), every insurer shall do all of the following: |
| 14 | | (1) Educate the insurer's staff, including any third |
| 15 | | parties contracted with the insurer to review claims, |
| 16 | | conduct utilization reviews, or make medical necessity |
| 17 | | determinations about the utilization review criteria. |
| 18 | | (2) Make the educational program available to other |
| 19 | | stakeholders, including the insurer's participating or |
| 20 | | contracted providers and potential participants, |
| 21 | | beneficiaries, or covered lives. The education program |
| 22 | | must be provided at least once a year, in-person or |
| 23 | | digitally, or recordings of the education program must be |
| 24 | | made available to the aforementioned stakeholders. |
| 25 | | (3) Provide, at no cost, the utilization review |
| 26 | | criteria and any training material or resources to |
|
| | 10400HB4585ham001 | - 27 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | providers and insured patients upon request. For |
| 2 | | utilization review criteria not concerning level of care |
| 3 | | placement, continued stay, transfer, discharge, or other |
| 4 | | patient care decisions used by the insurer pursuant to |
| 5 | | subsection (m), the insurer may place the criteria on a |
| 6 | | secure, password-protected website so long as the access |
| 7 | | requirements of the website do not unreasonably restrict |
| 8 | | access to insureds or their providers. No restrictions |
| 9 | | shall be placed upon the insured's or treating provider's |
| 10 | | access right to utilization review criteria obtained under |
| 11 | | this paragraph at any point in time, including before an |
| 12 | | initial request for authorization. |
| 13 | | (4) Track, identify, and analyze how the utilization |
| 14 | | review criteria are used to certify care, deny care, and |
| 15 | | support the appeals process. |
| 16 | | (5) Conduct interrater reliability testing to ensure |
| 17 | | consistency in utilization review decision making that |
| 18 | | covers how medical necessity decisions are made; this |
| 19 | | assessment shall cover all aspects of utilization review |
| 20 | | as defined in subsection (h). |
| 21 | | (6) Run interrater reliability reports about how the |
| 22 | | clinical guidelines are used in conjunction with the |
| 23 | | utilization review process and parity compliance |
| 24 | | activities. |
| 25 | | (7) Achieve interrater reliability pass rates of at |
| 26 | | least 90% and, if this threshold is not met, immediately |
|
| | 10400HB4585ham001 | - 28 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | provide for the remediation of poor interrater reliability |
| 2 | | and interrater reliability testing for all new staff |
| 3 | | before they can conduct utilization review without |
| 4 | | supervision. |
| 5 | | (8) Maintain documentation of interrater reliability |
| 6 | | testing and the remediation actions taken for those with |
| 7 | | pass rates lower than 90% and submit to the Department of |
| 8 | | Insurance or, in the case of Medicaid managed care |
| 9 | | organizations, the Department of Healthcare and Family |
| 10 | | Services the testing results and a summary of remedial |
| 11 | | actions as part of parity compliance reporting set forth |
| 12 | | in subsection (k) of Section 370c.1. |
| 13 | | (r) This Section applies to all health care services and |
| 14 | | benefits for the diagnosis, prevention, and treatment of |
| 15 | | mental, emotional, nervous, or substance use disorders or |
| 16 | | conditions covered by an insurance policy, including |
| 17 | | prescription drugs. |
| 18 | | (s) This Section applies to an insurer that amends, |
| 19 | | delivers, issues, or renews a group or individual policy of |
| 20 | | accident and health insurance or a qualified health plan |
| 21 | | offered through the health insurance marketplace in this State |
| 22 | | providing coverage for hospital or medical treatment and |
| 23 | | conducts utilization review as defined in this Section, |
| 24 | | including Medicaid managed care organizations, and any entity |
| 25 | | or contracting provider that performs utilization review or |
| 26 | | utilization management functions on an insurer's behalf. |
|
| | 10400HB4585ham001 | - 29 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | (t) If the Director determines that an insurer has |
| 2 | | violated this Section, the Director may, after appropriate |
| 3 | | notice and opportunity for hearing, by order, assess a civil |
| 4 | | penalty between $1,000 and $5,000 for each violation. Moneys |
| 5 | | collected from penalties shall be deposited into the Parity |
| 6 | | Advancement Fund established in subsection (i) of Section |
| 7 | | 370c.1. |
| 8 | | (u) An insurer shall not adopt, impose, or enforce terms |
| 9 | | in its policies or provider agreements, in writing or in |
| 10 | | operation, that undermine, alter, or conflict with the |
| 11 | | requirements of this Section. |
| 12 | | (v) The provisions of this Section are severable. If any |
| 13 | | provision of this Section or its application is held invalid, |
| 14 | | that invalidity shall not affect other provisions or |
| 15 | | applications that can be given effect without the invalid |
| 16 | | provision or application. |
| 17 | | (w) Beginning January 1, 2027 2026, coverage for medically |
| 18 | | necessary treatment of mental, emotional, or nervous, or |
| 19 | | substance use disorders or conditions shall comply with the |
| 20 | | following requirements: |
| 21 | | (1) No policy shall require prior authorization for |
| 22 | | outpatient or partial hospitalization services for |
| 23 | | treatment of mental, emotional, or nervous, or substance |
| 24 | | use disorders or conditions provided by a physician |
| 25 | | licensed to practice medicine in all branches, a licensed |
| 26 | | clinical psychologist, a licensed clinical social worker, |
|
| | 10400HB4585ham001 | - 30 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | a licensed clinical professional counselor, a licensed |
| 2 | | marriage and family therapist, a licensed speech-language |
| 3 | | pathologist, or any other type of licensed, certified, or |
| 4 | | legally authorized provider, including trainees working |
| 5 | | under the supervision of a licensed health care |
| 6 | | professional listed under this subsection, or facility |
| 7 | | whose outpatient or partial hospitalization services the |
| 8 | | policy covers for treatment of mental, emotional, or |
| 9 | | nervous, or substance use disorders or conditions. Such |
| 10 | | coverage may be subject to concurrent and retrospective |
| 11 | | review consistent with the utilization review provisions |
| 12 | | in subsection (b), subsections (h) through (n), and |
| 13 | | Section 370c.1. Nothing in this paragraph (1) supersedes a |
| 14 | | health maintenance organization's referral requirement for |
| 15 | | services from nonparticipating providers. An insurer may |
| 16 | | require providers or facilities to notify the insurer of |
| 17 | | the initiation of treatment as specified in this |
| 18 | | subsection, except to the extent prohibited by Section |
| 19 | | 370c.1 with respect to treatment limitations in a benefit |
| 20 | | classification or subclassification. No such coverage |
| 21 | | shall be subject to concurrent review for any services |
| 22 | | furnished before an applicable notification deadline, |
| 23 | | subject to the following: |
| 24 | | (A) In the case of outpatient treatment, for an |
| 25 | | insurer that is not a Medicaid managed care |
| 26 | | organization, the insurer may set a notification |
|
| | 10400HB4585ham001 | - 31 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | deadline of 2 business days after the initiation of |
| 2 | | the covered person's treatment. A Medicaid managed |
| 3 | | care organization may set a deadline of 24 hours after |
| 4 | | the initiation of treatment. If the Medicaid managed |
| 5 | | care organization is not capable of accepting the |
| 6 | | notification in accordance with the contractual |
| 7 | | protocol within the 24-hour period following |
| 8 | | initiation, the treatment provider or facility shall |
| 9 | | have one additional business day to provide the |
| 10 | | notification to the Medicaid managed care |
| 11 | | organization. |
| 12 | | (B) In the case of a partial hospitalization |
| 13 | | program, for an insurer that is not a Medicaid managed |
| 14 | | care organization, the insurer may set a notification |
| 15 | | deadline of 48 hours after the initiation of the |
| 16 | | covered person's treatment. A Medicaid managed care |
| 17 | | organization may set a deadline of 24 hours after the |
| 18 | | initiation of treatment. If the Medicaid managed care |
| 19 | | organization is not capable of accepting the |
| 20 | | notification in accordance with the contractual |
| 21 | | protocol during the 24-hour period following |
| 22 | | initiation, the treatment provider or facility shall |
| 23 | | have one additional business day to provide the |
| 24 | | notification to the Medicaid managed care |
| 25 | | organization. |
| 26 | | (2) No policy shall require prior authorization for |
|
| | 10400HB4585ham001 | - 32 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | inpatient treatment at a hospital for mental, emotional, |
| 2 | | or nervous, or substance use disorders or conditions at a |
| 3 | | participating provider. Additionally, no such coverage |
| 4 | | shall be subject to concurrent review for the first 72 |
| 5 | | hours after admission, provided that the provider must |
| 6 | | notify the insurer of both the admission and the initial |
| 7 | | treatment plan within 48 hours of admission. A discharge |
| 8 | | plan must be fully developed and continuity services |
| 9 | | prepared to meet the patient's needs and the patient's |
| 10 | | community preference upon release. Recommended level of |
| 11 | | care placements identified in the discharge plan shall |
| 12 | | comply with generally accepted standards of care, as |
| 13 | | defined in subsection (h). |
| 14 | | (A) If the provider satisfies the conditions of |
| 15 | | paragraph (2), then the insurer shall approve coverage |
| 16 | | of the recommended level of care, if applicable, upon |
| 17 | | discharge subject to concurrent review. |
| 18 | | (B) Nothing in this paragraph supersedes a health |
| 19 | | maintenance organization's referral requirement for |
| 20 | | services from nonparticipating providers upon a |
| 21 | | patient's discharge from a hospital or facility. |
| 22 | | (C) Concurrent review for such coverage must be |
| 23 | | consistent with the utilization review provisions in |
| 24 | | subsection (b) and subsections (h) through (n). |
| 25 | | (D) In this subsection, residential treatment that |
| 26 | | is not otherwise identified in the discharge plan is |
|
| | 10400HB4585ham001 | - 33 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | not inpatient hospitalization. |
| 2 | | (3) Treatment provided under this subsection may be |
| 3 | | reviewed retrospectively. If coverage is denied |
| 4 | | retrospectively, neither the insurer nor the participating |
| 5 | | provider shall bill, and the insured shall not be liable, |
| 6 | | for any treatment under this subsection through the date |
| 7 | | the adverse determination is issued, other than any |
| 8 | | copayment, coinsurance, or deductible for the stay through |
| 9 | | that date as applicable under the policy. Coverage shall |
| 10 | | not be retrospectively denied for the first 72 hours of |
| 11 | | admission to inpatient hospitalization for treatment of |
| 12 | | mental, emotional, or nervous, or substance use disorders |
| 13 | | or conditions, or before the applicable deadline under |
| 14 | | paragraph (1) of this subsection for outpatient treatment |
| 15 | | or partial hospitalization programs, at a participating |
| 16 | | provider except: |
| 17 | | (A) upon reasonable determination that the |
| 18 | | inpatient mental health treatment was not provided; |
| 19 | | (B) upon determination that the patient receiving |
| 20 | | the treatment was not an insured, enrollee, or |
| 21 | | beneficiary under the policy; |
| 22 | | (C) upon material misrepresentation by the patient |
| 23 | | or health care provider. In this item (C), "material" |
| 24 | | means a fact or situation that is not merely technical |
| 25 | | in nature and results or could result in a substantial |
| 26 | | change in the situation; |
|
| | 10400HB4585ham001 | - 34 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | (D) upon determination that a service was excluded |
| 2 | | under the terms of coverage. In that case, the |
| 3 | | limitation to billing for a copayment, coinsurance, or |
| 4 | | deductible shall not apply; |
| 5 | | (E) for outpatient treatment or partial |
| 6 | | hospitalization programs only, upon determination that |
| 7 | | a service was not medically necessary consistent with |
| 8 | | subsections (h) through (n); or |
| 9 | | (F) upon determination that the patient did not |
| 10 | | consent to the treatment and that there was no court |
| 11 | | order mandating the treatment. |
| 12 | | Nothing in this subsection shall be construed to |
| 13 | | require a policy to cover any health care service excluded |
| 14 | | under the terms of coverage. |
| 15 | | This subsection does not apply to coverage for any |
| 16 | | prescription or over-the-counter drug. |
| 17 | | Nothing in this subsection shall be construed to |
| 18 | | require the medical assistance program to reimburse for |
| 19 | | services not covered by the medical assistance program as |
| 20 | | authorized by the Illinois Public Aid Code or the |
| 21 | | Children's Health Insurance Program Act. |
| 22 | | (x) Notwithstanding any provision of this Section, nothing |
| 23 | | shall require the medical assistance program under Article V |
| 24 | | of the Illinois Public Aid Code or the Children's Health |
| 25 | | Insurance Program Act to violate any applicable federal laws, |
| 26 | | regulations, or grant requirements, including requirements for |
|
| | 10400HB4585ham001 | - 35 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | utilization management, or any State or federal consent |
| 2 | | decrees. Nothing in subsection (g) or (w) shall prevent the |
| 3 | | Department of Healthcare and Family Services from requiring a |
| 4 | | health care provider to use specified level of care, |
| 5 | | admission, continued stay, or discharge criteria, including, |
| 6 | | but not limited to, those under Section 5-5.23 of the Illinois |
| 7 | | Public Aid Code, as long as the Department of Healthcare and |
| 8 | | Family Services, subject to applicable federal laws, |
| 9 | | regulations, or grant requirements, including requirements for |
| 10 | | utilization management, does not require a health care |
| 11 | | provider to seek prior authorization or concurrent review from |
| 12 | | the Department of Healthcare and Family Services, a Medicaid |
| 13 | | managed care organization, or a utilization review |
| 14 | | organization under the circumstances expressly prohibited by |
| 15 | | subsections (g) and (w). Nothing in this Section prohibits a |
| 16 | | health plan, including a Medicaid managed care organization, |
| 17 | | from conducting reviews for medical necessity, clinical |
| 18 | | appropriateness, safety, fraud, waste, or abuse and reporting |
| 19 | | suspected fraud, waste, or abuse according to State and |
| 20 | | federal requirements. Nothing in this Section limits the |
| 21 | | authority of the Department of Healthcare and Family Services |
| 22 | | or another State agency, or a Medicaid managed care |
| 23 | | organization on the State agency's behalf, to (i) implement or |
| 24 | | require programs, services, screenings, assessments, tools, or |
| 25 | | reviews to comply with applicable federal law, federal |
| 26 | | regulation, federal grant requirements, any State or federal |
|
| | 10400HB4585ham001 | - 36 - | LRB104 17523 BAB 36484 a |
|
|
| 1 | | consent decrees or court orders, or any applicable case law, |
| 2 | | such as Olmstead v. L.C., 527 U.S. 581 (1999), or (ii) |
| 3 | | administer or require programs, services, screenings, |
| 4 | | assessments, tools, or reviews established under State or |
| 5 | | federal laws, rules, or regulations in compliance with State |
| 6 | | or federal laws, rules, or regulations, including, but not |
| 7 | | limited to, the Children's Mental Health Act and the Mental |
| 8 | | Health and Developmental Disabilities Administrative Act. |
| 9 | | (y) (Blank). |
| 10 | | (Source: P.A. 103-426, eff. 8-4-23; 103-650, eff. 1-1-25; |
| 11 | | 103-1040, eff. 8-9-24; 104-28, eff. 1-1-26; 104-417, eff. |
| 12 | | 8-15-25.) |
| 13 | | Section 99. Effective date. This Act takes effect upon |
| 14 | | becoming law.". |